- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Hitachi forms nuclear medicine division
Japanese vendor Hitachi Medical of Tokyo has formed a new nuclearmedicine division to handle direct sales in North America of itsgamma cameras. The move culminates Hitachi's comeback in the modality,which began when Summit Nuclear stopped marketing the
Japanese vendor Hitachi Medical of Tokyo has formed a new nuclearmedicine division to handle direct sales in North America of itsgamma cameras. The move culminates Hitachi's comeback in the modality,which began when Summit Nuclear stopped marketing the Hitachiproducts following the merger of Summit and Sopha Medical (SCAN10/11/95).
Hitachi's Nuclear Medicine Products Division will be based inTwinsburg, OH, and will be a subsidiary of Hitachi Medical Corporationof America, which is based in Tarrytown, NY. Former Summit executiveGary Enos is general manager of the division.
At last month's Radiological Society of North America meeting,Hitachi displayed SpectraDigital V250 DSP, the company's variable-angledual-head gamma camera. The company also had panels on 511-keVcollimation and a work-in-progress Coincidence Detection Reconstruction(CDR) technique.
Hitachi is also developing a new nuclear medicine workstation,SpectraDigital 300SS, which is based on a Hewlett-Packard platformwith applications software developed in cooperation with MedasysDigital Systems. The computer is expected to be available earlythis year.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
